LEXX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lexaria Bioscience Corp (LEXX) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's financial performance is deteriorating, with significant revenue and net income declines. Additionally, there are no strong technical, trading, or sentiment indicators suggesting a compelling entry point. While the stock has a Buy rating from analysts, the lowered price target and lack of positive catalysts make it prudent to hold off on investing.
The MACD is slightly positive but contracting, RSI is neutral at 51.731, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot point of 0.753, with key support at 0.665 and resistance at 0.841. Overall, the technical indicators suggest a neutral trend.
The company's DehydraTECH-semaglutide showed a 48% reduction in side effects compared to Rybelsus in its Phase 1b study.
The Phase 1b study showed less robust performance in body weight reduction compared to Rybelsus. Additionally, the company's financials are deteriorating, with revenue dropping to zero and significant declines in net income, EPS, and gross margin.
In Q1 2026, revenue dropped to 0 (-100% YoY), net income dropped to -1,595,007 (-41.01% YoY), EPS dropped to -0.07 (-56.25% YoY), and gross margin dropped to 0 (-100% YoY). The company's financials indicate significant challenges.
H.C. Wainwright analyst Yi Chen lowered the price target from $4 to $1.50 while maintaining a Buy rating. The lowered price target reflects concerns about the company's performance in its recent study and overall outlook.
